Evaluation on a six-dose treatment of anti CD 20 monoclonal antibody in patients with refractory follicular lymphoma

Citation
A. Aviles et al., Evaluation on a six-dose treatment of anti CD 20 monoclonal antibody in patients with refractory follicular lymphoma, CANC BIO R, 16(2), 2001, pp. 159-162
Citations number
10
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
ISSN journal
1084-9785 → ACNP
Volume
16
Issue
2
Year of publication
2001
Pages
159 - 162
Database
ISI
SICI code
1084-9785(200104)16:2<159:EOASTO>2.0.ZU;2-H
Abstract
Treatment of refractory follicular lymphoma with monoclonal antibody CD 20 has been proven to be a. good therapeutic option. However, most studies use d four weekly doses and rime to treatment failure (TTF) and overall surviva l (OS) could be considered very short: 11.0 and 13.6 months respectively. W e started a pilot study to evaluate if six infusions at the same doses and schedule could improve the outcome in these patients. Seventeen patients wi th refractory follicular lymphoma heavily treated with chemotherapy (> 2 re gimens), radiotherapy and biological modifiers were enrolled in a pilot stu dy. They received 6 weekly doses, at 375 mg/m(2), of monoclonal anti CD 20. In an intent to treat analysis, overall response was 76%, of which 47% (8 patients) were complete response and 5 patients were partial response. With a median follow-up of 28.6 months, 7 complete responders remain alive, fre e of disease, and 2 partial responses remain stable without additional trea tment. Median to TTF has not been reached; yet actuarial curves shotted tha t at 3 years, 53% of patients are alive. The four patients who were failure died secondary to armor progression. Overall survival (OS) at 3-year was 7 6%. Toxicity was mild all patients completed the schedule on time and doses . The addition of two doses of anti CD 20 clearly improved OS and TTF in a group of patients with refractory follicular lymphoma heavily treated and w ith poor prognostic factors. However the number is too short to draw defini tive conclusions; more clinical trials are necessary to determine if 4 or 6 doses of anti CD 20 therapy: are better in this setting of patients.